Skip to main content

Atherosclerosis clinical trials at UCSD

8 in progress, 5 open to eligible people

Showing trials for
  • Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

    open to eligible people ages 40-79

    CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.

    San Diego, California and other locations

  • Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).

    La Jolla, California and other locations

  • IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

    open to eligible people ages 18 years and up

    Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI. This is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive literature supporting the use of IVUS in PCI, utilization remains low in the United States. An increasing number of high-risk or complex lesions are being treated with PCI and we hypothesize that the impact of IVUS in these complex lesions will be of increased importance in reducing clinical adverse events while remaining cost effective.

    La Jolla, California and other locations

  • Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

    open to eligible people ages 18 years and up

    This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.

    San Diego, California and other locations

  • Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery

    open to eligible people ages 40 years and up

    Apply CT angiography, CT perfusion imaging and advanced image processing techniques to improve revascularization decision-making and surgical strategies in patients undergoing coronary artery bypass graft surgery.

    San Diego, California and other locations

  • Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

    Sorry, in progress, not accepting new patients

    The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.

    La Jolla, California and other locations

  • Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

    La Jolla, California and other locations

  • Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

    Sorry, in progress, not accepting new patients

    Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

    La Jolla, California and other locations

Our lead scientists for Atherosclerosis research studies include .

Last updated: